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Aims Cardiac resynchronization therapy (CRT) with or without a defibrillator reduces morbidity and mortality in selected
patients with heart failure (HF) but response can be variable. We sought to identify pre-implantation variables that
predict the response to CRT in a meta-analysis using individual patient-data.
Methods
and results
An individual patient meta-analysis of five randomized trials, funded by Medtronic, comparing CRT either with no active
device or with a defibrillator was conducted, including the following baseline variables: age, sex, New York Heart
Association class, aetiology, QRS morphology, QRS duration, left ventricular ejection fraction (LVEF), and systolic
blood pressure. Outcomes were all-cause mortality and first hospitalization for HF or death. Of 3782 patients in sinus
rhythm, median (inter-quartile range) age was 66 (58–73) years, QRS duration was 160 (146–176) ms, LVEF was 24
(20–28)%, and 78% had left bundle branch block. A multivariable model suggested that only QRS duration predicted
the magnitude of the effect of CRT on outcomes. Further analysis produced estimated hazard ratios for the effect of
CRT on all-cause mortality and on the composite of first hospitalization for HF or death that suggested increasing
benefitwith increasingQRSduration, the 95% confidenceboundsexcluding1.0 at140 ms foreachendpoint, suggesting
a high probability of substantial benefit from CRT when QRS duration exceeds this value.
Conclusion QRS duration is a powerful predictor of the effects of CRT on morbidity and mortality in patients with symptomatic HF
and left ventricular systolic dysfunction who are in sinus rhythm. QRS morphology did not provide additional information
about clinical response.
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Introduction
Despite the successes of pharmacological therapy for heart failure
(HF), many patients remain symptomatic, many relapse after a
period of control, the underlying disease often progresses and mor-
bidity and mortality still remain high. For some patients, symptoms
and/or prognosis can be improved by implanted devices. Cardiac
defibrillators (ICD) are designed to treat malignant ventricular
tachyarrhythmias and are highly effective in preventing sudden ar-
rhythmic death.1 Cardiac resynchronization therapy (CRT) has a
broader range of therapeutic benefits in appropriately selected
patients, including improvements in cardiac function symptoms and
quality of life and reductions in HF-related hospitalizations and
death.2,3 Devices with both CRT and ICD functions (CRT-D) are
often implanted and have been shown to be superior to an ICD
alone in improving outcome.4
Clinical trials are designed to show the average effect of an inter-
vention in the population enrolled and usually lack the power to
assess effects within subgroups. However, froma patient and clinician
perspective, estimating risks and benefits on an individual basis is
paramount. Clearly, CRT will sometimes fail to improve cardiac func-
tion, symptoms, or prognosis. This has spawned many observational
studies attempting to identify predictors of success or failure, usually
based on surrogate outcomes.5 –7 These may be unable to untangle
the therapeutic response to CRT from the natural history of the
underlying disease.5 Ideally, analyses to predict benefit or lack
thereof should be done on data from randomized trials. Several
meta-analyses using aggregate data from trials of CRT have been
reported but these are limited by variable reporting of subgroup
data and cannot reliably investigate potential interactions between
variables, for example QRS duration and morphology, conferred
by access to individual patient data.2,4 Accordingly, we undertook
an individual patient meta-analysis on data from five landmark rando-
mized clinical trials of CRT.
Methods
All five randomized controlled trials comparing CRT compared with no
CRT with ≥6 months of follow-up for which Medtronic could supply in-
dividual patient data were used in this analysis. Two relevant large trials,
COMPANION and MADIT-CRT, were not included as the authors did
not have access to individual patient data. Data were pooled on 4317
patients comparing either CRT with no active control (no device or
back-up pacing; CARE-HF,8,9 MIRACLE,10 REVERSE11,12) or CRT-D
with ICD (REVERSE,11,12 MIRACLE ICD,13,14 RAFT15). In order to
create a more homogeneous population, patients in New York Heart As-
sociation (NYHA) class I (107 patients from REVERSE) and those in atrial
fibrillation or with a pre-existing pacemaker (338 patients from RAFT)
were excluded.
Statistical analyses were done using the intention-to-treat principle
and included patients who failed to receive their assigned treatment. In
CARE-HF, 19 (4.6%) patients failed to receive a CRT device after one
or more attempts. In RAFT, five patients (0.6%) failed to receive an
ICD and 53 (5.9%) a CRT-D. Successful implantation prior to randomiza-
tion was required in the MIRACLE, MIRACLE ICD, and REVERSE trials.
Implant failure rates in these three studies were 7.8, 10.8, and 3.3%,
respectively.
The following baseline variables were included in the analyses: age, sex,
NYHA class, aetiology, QRS morphology, QRS duration, left ventricular
ejection fraction (LVEF), and systolic blood pressure. Core-laboratory
values were used for ECG measurements in CARE-HF, REVERSE, and
RAFT, and for echocardiographic assessment of LVEF in all studies
except RAFT.
The two outcomes of interest specified for this analysis were all-cause
mortality and the composite of hospitalization for HF or all-cause mortal-
ity. Hospitalizations were adjudicated by committees blind to treatment
allocation in each study.
Statistics
Continuously distributed data are shown as both mean and standard de-
viation and median, inter-quartile range (IQR), and full range (FR). Cat-
egorical data are shown as percentages. Because data were pooled
from multiple studies which may be heterogeneous for one or more un-
accounted factors affecting outcomes, shared frailty models were used
for both endpoints with random effects for each study following a
gamma distribution. These models included main effects of the covariates
defined above as well as corresponding interaction effects with CRT.
Quantitative variables (age, LVEF, QRS duration, systolic blood pressure)
were treated as continuous variables in the models. QRS duration was
normalized by subtracting 120 ms from each QRS value. Patients in
NYHA class III were enrolled in all studies except REVERSE and served
as the default for calculating hazard rate.
Additional models were fitted for subgroup analyses to estimate CRT
effects among specific homogenous patient groups. Age and systolic
blood pressure were split by quartile, whereas LVEF was partitioned by
pre-specified cut-offs of ≤15, 16–20, 21–30, 31–35, and .35%.
Other subgroups were categorical, including QRS morphology [left
bundle branch block (LBBB) or not]. For each subgroup, a univariate
frailty model was fitted, with CRT as a fixed effect and random study
effects accounted for and the corresponding hazard ratio (HR) and
95% confidence bound for the HR of CRT compared with control was
calculated.
To investigate the relationship between QRS duration and the effect
of CRT, Cox proportional hazards models were fitted for each pre-
specified endpoint with all significant main effects from the frailty
model, main effects for CRT and normalized QRS duration, and the inter-
action effect for normalized QRS duration and CRT. The model tested a
linear interaction effect for QRS duration and CRT, and a nonlinear
interaction effect incorporating a third-order P-spline with 4 degrees of
freedom. The latter interaction term was tested to determine whether
the HR for CRT changes over different QRS duration subgroups in a non-
linear manner. P-splines allow for fitting complicated curvilinear patterns
and so were utilized. The predicted values from each model were used to
determine and plot the estimated HR of CRT for QRS duration as a con-
tinuous measure. To assess the variability of the results, 95% bootstrap
confidence intervals were determined for each set of HRs. While
random study effects were not incorporated into these models, sampling
with replacement was performed such that each study/treatment arm
combination provided the same number of subjects in each sample as
in the original cohort.
Results
Altogether, 3872 (76%) patients were included in this analysis
(Figure 1; Table 1). The median (IQR) age of patients was 66
(58–73) years, 868 (22%) were women (Table 2), 1995 (52%) were
in NYHA class III or IV, and 2232 (58%) had ischaemic heart
disease, including 1926 men (64% of men) and 306 women (35% of
women). Only 81 patients in REVERSE were assigned to receive
CRT or back-up pacing, and, therefore, among NYHA II patients
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who were enrolled, the comparison was predominantly CRT-D vs.
ICD. The median value for LVEF (IQR) was 24 (20–28)%; it was
116 (105–130) mmHg for systolic blood pressure and was 160
(146–176) ms for QRS duration, with 78% having LBBB.
Comparing patients assigned to CRT/CRT-D or to the control
group in the whole population, the HR for all-cause mortality was
0.66 (95% CI 0.57–0.77), and it was 0.65 (95% CI 0.58–0.74) for
death or HF hospitalization (Figure 2A and B).
A significant interaction between CRT and QRS duration (Table 3)
was observed, for both the composite outcome (P, 0.0001) and all-
cause mortality alone (P ¼ 0.0013), suggesting that patients with
longer QRS durations derive greater benefit from CRT. Use of
P-splines to examine the relationship between the effect of CRT
and QRS duration as a continuous variable demonstrated a progres-
sive increase in the benefit of CRT for both endpoints as QRS
duration increased (Figure 3). The analyses yielded a significant
nonlinear relationship with regard to the composite of death/HF
hospitalization (P ¼ 0.0039), with a plateau of effect beyond
180 ms for the composite outcome, but not for mortality alone
(P ¼ 0.3454). The estimated HR crossed 1.0 at 126 ms for all-cause
mortality and at 132 ms for the composite, suggesting possible
benefit from CRT when QRS duration exceeds these values. The
95% confidence bounds excluded 1.0 beginning at 140 ms for
each endpoint, providing robust evidence of benefit from CRT
when QRS duration exceeds this limit.
Interactions between CRT and other covariates were not signifi-
cant in a multivariable model that included QRS duration. Similar
reductions in all-cause mortality were observed with CRT regardless
of whether the comparator was or was not an ICD and regardless of
age, sex, NYHA class, aetiology, systolic blood pressure, or use of
beta-blockers (Figure 4). Subgroup analyses for time to first compos-
ite event of HF hospitalization or death showed similar results
(Figure 5). Patients who did not have LBBB appeared to have less
benefit from CRT, especially in the composite outcome, but differ-
ences were not statistically significant. QRS duration was similar in
patients with LBBB [median (IQR) 160 (150–180) ms] and RBBB
[160 (150–172) ms] but shorter among patients with a non-specific
intra-ventricular conduction delay [139 (128–160) ms], which may
account for the trend to less reduction in mortality in the latter
group. Removal of the QRS duration interaction term strengthened
the interaction term between QRS morphology and the composite
outcome (P ¼ 0.031), but not for mortality alone (P ¼ 0.63).
Figure 1 CONSORT flow diagram showing reasons for excluding patients from analysis.
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Table 1 Characteristics of five studies included in the patient-level meta-analysis of cardiac resynchronization therapy
Study Patients Randomization Sample Median follow-upa
MIRACLE NYHA III– IV, QRS ≥ 130 ms, EF ≤ 35% 1:1 (CRT-P vs. VDI-30) 541 6 months
MIRACLE ICD NYHA II– IV, QRS ≥ 130 ms, EF ≤ 35%, ICD indication 1:1 (CRT-D vs. DDI-35) 555 6 months
CARE-HF NYHA III– IV, QRS ≥ 120 ms, EF ≤ 35% 1:1 (CRT-P vs. OMT) 813 29 months (35 months for mortality)
REVERSE NYHA I–II, QRS ≥ 120 ms, EF ≤ 40% 2:1 (CRT+D vs. VVI-35) 610 12 months (24 months, EU cohort)
RAFT NYHA II– III, QRS ≥ 120 ms (pQRS ≥ 200 ms), EF ≤ 30% 1:1 (CRT-D vs. ICD) 1798 40 months
aFollow-up is for median of the randomized period only.
CRT-P, cardiac resynchronization therapy - pacemaker only, with no defibrillator function; OMT, optimal medical therapy.
IPD meta-analysis of trials of CRT 3549
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Table 2 Patient characteristics
Patient characteristics CRT-P
(n 5 735)
CRT-D
(n5 1288)
OMT+ back-up
pacing (n 5 700)
ICD
(n5 1149)
Total
(n 5 3872)
Gender, n (%)
Male 531 (72.2) 1050 (81.5) 503 (71.9) 920 (80.1) 3004 (77.6)
Female 204 (27.8) 238 (18.5) 197 (28.1) 229 (19.9) 868 (22.4)
Age, years at baseline visit
Mean+ standard deviation 65+10 65+10 65+11 65+10 65+10
Median 66 66 66 66 66
25th percentile–75th percentile 58–73 58–72 58–72 58–73 58–73
Minimum–maximum 33–88 23–89 28–94 20–89 20–94
Baseline left ventricular ejection fraction
Mean+ standard deviation 25+7 24+6 25+7 23+6 24+6
Median 24 24 25 24 24
25th percentile–75th percentile 21–29 20–28 21–30 20–27 20–28
Minimum–maximum 9–53 7–52 8–48 6–45 6–53
Number (%) of patients with LVEF availablea 693 (94.3) 1287 (99.9) 674 (96.3) 1149 (100) 3803 (98.2)
Baseline QRS duration
Mean+ standard deviation 165+21 158+24 164+20 159+24 161+23
Median 160 160 160 160 160
25th percentile–75th percentile 152–180 140–174 152–180 140–176 146–176
Minimum–maximum 94–240 93–263 100–240 80–230 80–263
Number (%) of patients with QRS available 727 (98.9) 1288 (100) 690 (98.6) 1149 (100) 3854 (99.5)
Baseline supine systolic BP
Mean+ standard deviation 117+18 119+18 117+18 118+18 118+18
Median 115 118 115 118 116
25th percentile–75th percentile 105–130 106–130 105–128 106–130 105–130
Minimum–maximum 75–184 72–205 73–180 75–185 72–205
Number (%) of patients with measurement 732 (99.6) 1283 (99.6) 696 (99.4) 1145 (99.7) 3856 (99.6)
Baseline supine diastolic BP
Mean+ standard deviation 70+10 69+11 69+11 69+10 69+11
Median 70 70 70 70 70
25th percentile–75th percentile 60–79 60–76 60–78 60–76 60–77
Minimum–maximum 36–101 35–112 40–110 40–120 35–120
Number (%) of patients with measurement 732 (99.6) 1283 (99.6) 696 (99.4) 1145 (99.7) 3856 (99.6)
NYHA classification, n (%)
NYHA II 60 (8.2) 963 (74.8) 21 (3.0) 833 (72.5) 1877 (48.5)
NYHA III 625 (85.0) 303 (23.5) 624 (89.1) 297 (25.8) 1849 (47.8)
NYHA IV 50 (6.8) 22 (1.7) 55 (7.9) 19 (1.7) 146 (3.8)
Morphology, n (%)
Left bundle branch blocka 637 (86.7) 963 (74.8) 596 (85.1) 840 (73.1) 3036a (78.4)
Right bundle branch blockb 37 (5.0) 124 (9.6) 45 (6.4) 140 (12.2) 346 (8.9)
Neither 47 (6.4) 205 (15.9) 39 (5.6) 176 (15.3) 467 (12.1)
Ischaemic heart disease, n (%) 352 (47.9) 829 (64.4) 319 (45.6) 732 (63.7) 2232 (57.6)
Beta-blocker use at baseline 509 (69.3) 1101 (85.5) 454 (64.9) 942 (82.0) 3006 (77.6)
Duration of follow-up (months)
Mean+ standard deviation 21.3+15.0 28.3+21.4 19.7+15.0 28.5+21.4 25.5+19.7
Median 23.9 23.7 16.4 24.1 23.7
25th percentile–75th percentile 6–35.2 11.1–44.7 5.8–33.6 6.5–43.8 6.2–38.8
Minimum–maximum 0.2–51.6 0–89.5 0.1–52.4 0.3–88.8 0–89.5
aLBBB status not known for some subjects (15 CRT-P subjects and 22 OMT subjects).
bThere were 14 subjects reported to have both LBBB and RBBB; these are counted in both groups.
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Discussion
This individual patient data meta-analysis confirms the substantial
benefits of CRT on morbidity and mortality in patients with mild,
moderate, or severe symptoms of HF who have left ventricular sys-
tolic dysfunction, are in sinus rhythm, and have a prolonged QRS.
After adjusting for QRS duration, LBBB morphology was not a signifi-
cant predictor of the benefits of CRT. Patients with non-specific
intra-ventricular conduction delay had shorter QRS duration and
this may account for reports suggesting that such patients receive
less benefit from CRT.7,16–20 Age, sex, aetiology of disease, LVEF,
blood pressure, and use of beta-blockers had no important, inde-
pendent influence on the effects of CRT on morbidity or mortality.
Furthermore, the benefits of CRT were similar whether or not the
comparator group received an ICD. The failure of most patient char-
acteristics to predict the effect of CRT in this large individual patient
meta-analysis contrasts with that from some individual randomized
trials21,22 and many smaller observational studies, that variously
suggest that older patients, men, those with RBBB, and patients
with ischaemic heart disease benefit less than others from
CRT.5,7,23,24 Individual randomized trials may lack statistical power
to investigate these issues, and observational studies may be unable
to untangle the treatment effect of CRT from the natural history of
disease.25 Use of individual patient data, analysis of QRS as a
continuous variable, and the ability to investigate interactions
betweenQRS durationandQRSmorphologyallowedamore sophis-
ticated and granular analysis than previous meta-analyses that used
only aggregated subgroup data. A more detailed analysis of subtle dif-
ferences in QRS morphology might have identified patterns that pro-
vided prognostic information in addition to QRS duration, but such
information was not available. Inclusion of a larger number of patients
from additional trials would have increased the power to identify or
refute any additional contribution from QRS morphology.
Our analysis may inform and simplify existing guidelines about the
selection of patients for CRT. Current joint guidelines from the
American Heart Association and American College of Cardiology
strongly recommend CRT implantation in patients with an LVEF
≤35% if the QRS duration is ≥150 ms and LBBB is present.26 The
Heart Failure Society of America guidelines27 strongly recommend
CRT only when both QRS is ≥150 ms and RBBB morphology is
absent, with a weaker recommendation when QRS is 120–150 ms
regardless of BBB morphology. The 2012 joint European Heart
Rhythm Association and Heart Rhythm Society expert consensus
statement also suggested that QRS duration .150 ms was asso-
ciated with a more consistent response and that non-LBBB morph-
ology was associated with a poor response or even harm.28
European Society of Cardiology guidelines29 strongly recommend
CRT only when LBBB is present and QRS is ≥130 ms if in NYHA
Figure2 Overall effect of cardiac resynchronization therapy vs. control on all-cause mortality (A) and on death or heart failure hospitalization (B).
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class II or ≥120 ms if in NYHA class III, with a weaker recommenda-
tion for patients who have a QRS ≥ 150 ms in the absence of LBBB,
regardless of NYHA class.
Some guidelines have suggested that recommendations should be
based on the characteristics of patients actually enrolled in trials
rather than on the trial inclusion/exclusion criteria, which has some
merit but requires large data sets to explore effects in less prevalent
subgroups.30 Indeed, such recommendations are advocating, in
effect, that guidelines should be based on subgroups within trials
rather thantheoverall effect;mostclinical trialistswouldcautionother-
wise. It may also create a dilemma if treatment effects are identified in
patients who do not appear to fit the study inclusion criteria. Investiga-
tors often report a lower LVEF than measured by the central trial
laboratory, perhaps reflecting a bias introduced by the threshold
LVEF criterion required for study inclusion.31,32 In the current
analysis, patients with an LVEF.35% measured in the core echocardi-
ography laboratory appeared to derive similar benefit from CRT com-
pared with patients with a lower LVEFeven though the entry criteria of
most trials might have been expected to exclude such patients.
The precise mechanism(s) by which CRT delivers benefit remains
elusive.5,6 This analysis suggests that there is something about
electrical, and presumably electro-mechanical, delay that is funda-
mental to the effect of CRT. QRS prolongation is associated with
poorer ventricular function,33 but in contrast with QRS duration,
no significant association between the effect of CRT and baseline
LVEF was noted across the measured range. Improvement in left ven-
tricular function in the months after CRT implantation is associated
with a better prognosis.34– 36 However, patients with ischaemic
heart disease have substantially less improvement in ventricular func-
tion with CRT, presumably because of myocardial scar,37,38 and yet
the benefits of CRT on prognosis are remarkably similar in patients
with or without ischaemic heart disease.12,34,35,39 Improvement in
left ventricular function after CRT implantation may indicate that
the patient has more viable myocardium and therefore an intrinsically
better prognosis40 rather than providing an overriding mechanism by
which CRT delivers clinical benefit. Alternatively, patients with is-
chaemic heart disease may benefit in ways other than improved
LVEF, such as byarrhythmia suppression.41– 43 In somepatients, shor-
tened AV conduction and reduction in mitral regurgitation may be an
important mechanism of CRT effect. The rise in blood pressure that
occurs with successful CRT may exert secondary benefits but could
again just be a marker of improved cardiac function.44 Cardiac
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Main modelling results for time to all-cause mortality/heart failure hospitalization or mortality alone
Effect All-cause mortality/heart failure hospitalization All-cause mortality
Hazard ratio:
univariate
Hazard ratio:
multivariable
P-value for
multivariable
Hazard ratio:
univariate
Hazard ratio:
multivariable
P-value
multivariable
Main effects
ICD therapy N/A 1.172 0.6283 N/A 0.630 0.0500
CRT therapy N/A 1.046 0.9452 N/A 0.458 0.3803
Age at baseline 1.020 1.018 <0.0001 1.030 1.030 <0.0001
NYHA II 0.605 0.687 0.0004 0.658 0.658 0.0020
NYHA IV 2.771 2.180 <0.0001 2.444 2.444 0.0001
Left Bundle Branch Block 0.839 0.830 0.0820 0.825 0.825 0.1782
Ischaemic heart disease 1.519 1.394 0.0004 1.638 1.638 <0.0001
Gender: male 1.052 1.001 0.9897 1.131 1.131 0.3663
QRS duration 1.000 1.001 0.7061 1.004 1.004 0.0941
LVEF 0.963 0.965 <0.0001 0.956 0.956 <0.0001
Beta-blocker use at baseline 0.711 0.774 0.0093 0.700 0.700 0.0041
Systolic BP at baseline 0.988 0.990 0.0001 0.987 0.987 <0.0001
Interaction with effect of CRT
Age at baseline 0.998 1.000 0.9858 1.008 1.008 0.3832
NYHA II 0.959 0.820 0.1499 0.777 0.777 0.1654
NYHA IV 0.832 0.836 0.5334 0.800 0.800 0.5233
Left bundle branch block 0.663 0.785 0.1228 0.977 0.977 0.9157
Ischaemic heart disease 1.232 1.080 0.5996 1.045 1.045 0.8171
Gender: male 1.351 1.299 0.1234 1.173 1.173 0.4709
QRS duration 0.989 0.988 <0.0001 0.988 0.988 0.0013
LVEF 1.025 1.021 0.0625 1.016 1.016 0.2667
Beta-blocker use at baseline 0.975 1.034 0.8259 1.109 1.109 0.5897
Systolic BP at baseline 0.998 0.996 0.2735 0.998 0.998 0.7583
Frailty effect for study N/A N/A <0.0001 N/A N/A 0.1376
Values in bold are statistically significant at P, 0.05.
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resynchronization therapy could also prevent brady-arrhythmic
death, although this would only be noticed in studies such as
CARE-HF and COMPANION where the control group did not
receive a device.6 There may be no single mechanism by which
CRT exerts its effects and the dominant mechanism of benefit may
vary from one patient to the next and over time within an individual.6
This analysis was conducted using common, relatively simple vari-
ables that were available from all five trials. It does not preclude the
possibility that other markers of cardiac dyssynchrony are superior
to QRS duration in predicting benefit from CRT. However, the
reduced effect of CRT in patients with QRS duration ,140 ms
implies either that the individual benefit is small in such patients or
that only a few patients respond or that substantial benefit in some
patients is negatedbyharminothers.Whethermeasuresofventricular
dyssynchrony by imaging are able to identify a patient who is more
likely to benefit, and if so which measure, remains controversial.45
A randomized controlled trial enrolling patients with QRS, 130 ms
is addressing this question (enrolment recently stopped); results
will be presented at the European Society of Cardiology Congress in
2013.46
An important limitation of this analysis was the lack of access to in-
dividual patient data from two large trials that were funded by Boston
Scientific Incorporated. The COMPANION trial would have added a
further 1520 patients (308 assigned to the control group), predom-
inantly with NYHA class III or IV HF, a further 313 deaths, and
at least 594 events of death or first HF hospitalization.47 The
MADIT-CRT trials would have added a further 1555 patients (618
assigned to the control group) with NYHA class II HF and up to a
further 127 deaths and 372 events of death or first hospitalization.48
This compares with 662 deaths and 1082 events of death or first
Figure 3 Models showing hazard ratios (Y-axis and solid black line) and their 95% confidence intervals (dotted lines) for the effects of cardiac
resynchronization therapy vs. control with QRS plotted on the X-axis. (A) The relationship between the effect of cardiac resynchronization
therapy on all-cause mortality and QRS. (B) The corresponding relationship for heart failure hospitalization or death. The intersection of the
95% confidence interval and the line indicating a hazard ratio of 1.0 (no effect) indicates the QRS duration above which there is a high certainty
of response.
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hospitalization in the current analysis. Review of aggregate data from
these two trials reinforces our findings about the relationship of QRS
duration and the benefits of CRT and the relationship between QRS
morphology and QRS duration.16,24,47 In both COMPANION and
MADIT-CRT, longer QRS duration was associated with greater
benefit. In a univariate analysis of MADIT-CRT, despite substantial
reductions in cardiac volumes and improvement in LVEF, a trend
towards an increase in mortality was observed with CRT amongst
patients who did not have LBBB. However, there were few deaths
in MADIT-CRT amongst such patients, especially in the small
number randomized to the control group. This will have increased
the risk of a chance finding of an adverse effect of CRT in patients
without LBBB. Our univariate analysis also showed less benefit
with respect to the composite of mortality or HF hospitalization in
patients without LBBB. However, after adjusting for QRS duration,
outcomes were similar whether or not LBBB was present. QRS
morphology might play a role in predicting the effect of CRT, but
QRS duration appears consistently stronger. Individual patient
data-sets that include larger representation of subjects with RBBB
or non-specific intra-ventricular conduction delay are required to
explore how QRS duration and QRS morphology interact with the
effects of CRT on morbidity and mortality.
Care should be taken in extrapolating data gathered from patients
selected to participate in clinical trials to the wider population of
patients with HF who might be considered for CRT. However, the
heterogeneity of the studies, in terms of symptom severity, back-
ground therapy, and whether the intervention was CRT or CRT-D,
may be seen as a strength rather than a limitation of the analysis as
these differences did not appear to influence the benefits of CRT.
Trials with longer durations of follow-up will have accumulated
more events and had a greater influence on the results. Although
an absolute benefit of CRT on the composite outcome of first hospi-
talization for HF or death appeared within 6 months, the absolute
benefit for mortality was not obvious until 12–18 months. Short-
term trials will have contributed little to this part of the analysis.
In practical terms, this analysis suggests that the chancesof apatient
benefiting from CRT diminish when QRS is,140 ms. If the choice is
between CRT or no device, then renewed efforts at medical manage-
ment are justified rather than preferring device implantation. If the
choice is between CRT-D and ICD, then a lower decision threshold
Figure 4 Forest plot for univariate frailty models evaluating the effect of cardiac resynchronization therapy in pre-specified subgroups on
all-cause mortality.
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of 130 ms may be justified as the patient is already going to have
a procedure; there is evidence of benefit in patients with QRS
130–140 ms and QRS duration increases over time.49 Implanting a
CRT-D system initially may prevent the need for a later upgrade
with its attendant risk of complications.
In conclusion, this individual patient meta-analysis confirms the
benefits of CRT on morbidity and mortality in patients with mild,
moderate, or severe symptoms of HF who have moderate or
severe left ventricular systolic dysfunction and who are in sinus
rhythm with a QRS duration .140 ms. The clinical benefits of
CRT in patients with QRS durations between 120 and 140 ms are,
on average, smaller and/or less certain. After adjusting for QRS dur-
ation, in this analysis, QRS morphology was not a determinant of the
clinical response to CRT. Future analyses of these data will investigate
whether QRS duration or other variables can predict which patients
obtain symptomatic benefits from CRT.
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